Pharmaceuticals, Biotechnology and Life Sciences
LEXINGTON, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;–Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced today that Jesper Høiland has been appointed to…
DUBLIN–(BUSINESS WIRE)–The “The Pharmaceutical Industry in South Africa 2019” report has been added to ResearchAndMarkets.com’s offering. This report on the…
WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its…
AstraZeneca and Merck’s LYNPARZA Is the Only PARP Inhibitor in This Setting to Demonstrate an Improvement in Progression-Free Survival for…
PHILADELPHIA–(BUSINESS WIRE)–BTG plc (LSE: BTG), the global healthcare company, today announced the publication of a trial, “Antivenom Treatment is Associated…
Pfizer has received positive opinion recommending TALZENNA (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor
ULTOMIRIS has the potential to become the new standard of care forboth complement inhibitor-naïve patients and patients switching fromSOLIRIS (eculizumab) –
New data will be presented for risdiplam, an investigational oralsurvival motor neuron 2 (SMN2) splicing modifier for SMA, which isdesigned to increase and sustain SMN protein levels in the centralnervous system (CNS) and throughout the body.
Based on the source, the market was dominated by the bacteria-basedprobiotic supplements segment, with a 91% share in 2017. Most probioticsupplements include bacterial strains, of which, Lactobacillus sp andBifidobacterium sp are used widely for the maintenance of healthymicrobiota.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the participation of its…